

S3 Table. Characteristics of ctDNA positive patients

No	Age (yr)	FIGO stage	Histology	Peritoneal cytology	ctDNA
1	42	I	Clear cell	Positive	<i>PIK3CA</i> H1047R
2	54	I	Clear cell	Negative	<i>PIK3CA</i> E542K
3	76	III	Serous	Positive	<i>KRAS</i> G12/G13
4	48	I	Mucinous	Negative	<i>KRAS</i> G12/G13
5	57	II	Endometrioid	Negative	<i>KRAS</i> G12/G13
6	62	I	Clear cell	Negative	<i>PIK3CA</i> H1047R
7	80	IV	Serous	Negative	<i>KRAS</i> G12/G13
8	42	I	Clear cell	Positive	<i>PIK3CA</i> H1047R
9	33	III	Mucinous	Positive	<i>KRAS</i> G12/G13
10	53	III	Endometrioid	Positive	<i>KRAS</i> G12/G13
11	46	III	Clear cell	Positive	<i>PIK3CA</i> H1047R
12	57	II	Endometrioid	Positive	<i>KRAS</i> G12/G13
13	59	I	Carcinosarcoma	Positive	<i>KRAS</i> G12/G13
14	53	III	Clear cell	Positive	<i>KRAS</i> G12/G13
15	63	I	Endometrioid	Positive	<i>PIK3CA</i> H1047R
16	58	III	Clear cell	Positive	<i>PIK3CA</i> H1047R
17	61	III	Clear cell	Positive	<i>PIK3CA</i> E545K
18	38	I	Clear cell	Positive	<i>PIK3CA</i> E545K
19	64	I	Endometrioid	Positive	<i>KRAS</i> G12/G13
20	72	I	Endometrioid	Negative	<i>KRAS</i> G12/G13
21	52	I	Clear cell	Negative	<i>KRAS</i> G12/G13
22	54	II	Clear cell	Positive	<i>PIK3CA</i> E542K&H1047R
23	64	III	Clear cell	Positive	<i>PIK3CA</i> H1047R

ctDNA, circulating tumor DNA; FIGO, International Federation of Gynecology and Obstetrics.